Over the past decade, various molecular targets have been identified for the treatment of HCC, including VEGF (vascular endothelial growth factor), PD-1/PD-L1 (programmed death-ligand 1), and EGFR (epidermal growth factor receptor) [3]. This evidence concerns the gene CD274 and hepatocellular carcinoma.